Combined therapy of αPD-1 and Ad5/11-αCD3TAT-Trimer showed the highest frequency of systemic effector CD8+ T cells (Fig. EV5F) consistent with the effective immunoactivation in tumor tissue. The gene discussed is CD8A; the disease is neoplasm.